Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy

被引：14

作者：

Duval, X ^{[1
]}

Pajot, O

Le Moing, V

Longuet, P

Ecobichon, JL

Mentre, F

Leport, C

Vilde, JL

机构：

[1] Hop Bichat Claude Bernard, Dept Infect Dis, F-75877 Paris 18, France

[2] Hop Bichat Claude Bernard, Dept Biostat, F-75877 Paris 18, France

来源：

AIDS | 2004年 / 18卷 / 09期

关键词：

D O I：

10.1097/00002030-200406180-00016

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To reduce the number of daily pills for improving adherence to antiretrovirals, 17 protease inhibitor-treated patients receiving toxoplasmic encephalitis (TE) standard maintenance therapy were instead given cotrimoxazole 960 mg twice daily. After a median follow-up of 31 months, one relapsed after three months, TE relapse incidence = 2.1 cases per 100 patient-years (95% confidence interval, 0.05-11.3). This strategy could be useful for patients awaiting immune reconstitution which allows the interruption of TE maintenance therapy.

引用

页码：1342 / 1344

页数：3

共 10 条

[1] Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults [J].

Bartlett, JA ;

DeMasi, R ;

Quinn, J ;

Moxham, C ;

Rousseau, F .

AIDS, 2001, 15 (11) :1369-1377

[2] COTRIMOXAZOLE THERAPY OF TOXOPLASMA-GONDII ENCEPHALITIS IN AIDS PATIENTS [J].

CANESSA, A ;

DELBONO, V ;

DELEO, P ;

PIERSANTELLI, N ;

TERRAGNA, A .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (02) :125-130

[3]

DUVAL X, 2001, CURR TREATMENT OPTIO, V3, P113

[4] Pyrimethamine-clindamycin vs pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS [J].

Katlama, C ;

DeWit, S ;

ODoherty, E ;

VanGlabeke, M ;

Clumeck, N ;

Payen, MC ;

Mathiesen, L ;

Nielsen, JO ;

Pedersen, C ;

Dupont, B ;

Pialoux, G ;

Janbon, F ;

Reynes, J ;

Gallais, H ;

Mars, ME ;

Jeantils, V ;

Schneider, MC ;

Averous, V ;

Decazes, JM ;

DocoLecompte, T ;

Modai, J ;

Molina, JM ;

Blanc, A ;

Delfraissy, JF ;

Guillevin, L ;

Jarrousse, B ;

Sehouane, R ;

Trogoff, B ;

Armengaud, M ;

Marchou, B ;

Meurisse, JJ ;

Gentilini, M ;

Guichard, A ;

Rogeaux, O ;

Livrozet, JM ;

Touraine, JL ;

Sereni, D ;

Rousseau, F ;

Pesce, A ;

Coulaud, JP ;

Detruchis, P ;

Fegueux, S ;

Maslo, C ;

Matheron, S ;

Raffi, F ;

Bassetti, D ;

Canessa, A ;

DelBono, V ;

DeLeo, P ;

Terragna, A .

CLINICAL INFECTIOUS DISEASES, 1996, 22 (02) :268-275

[5]

MIRO J, 2000, 40 INT C ANT AG CHEM

[6] Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients:: The changes in opportunistic prophylaxis study [J].

Mussini, C ;

Pezzotti, P ;

Govoni, A ;

Borghi, V ;

Antinori, A ;

Monforte, AD ;

De Luca, A ;

Mongiardo, N ;

Cerri, MC ;

Chiodo, F ;

Concia, E ;

Bonazzi, L ;

Moroni, M ;

Ortona, L ;

Esposito, R ;

Cossarizza, A ;

De Rienzo, B .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05) :1635-1642

[7] A RETROSPECTIVE STUDY ABOUT THE USE OF COTRIMOXAZOLE AS DIAGNOSTIC SUPPORT AND TREATMENT OF SUSPECTED CEREBRAL TOXOPLASMOSIS IN AIDS [J].

SOLBREUX, P ;

SONNET, J ;

ZECH, F .

ACTA CLINICA BELGICA, 1990, 45 (02) :85-96

[8] Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS [J].

Torre, D ;

Casari, S ;

Speranza, F ;

Donisi, A ;

Gregis, G ;

Poggio, A ;

Ranieri, S ;

Orani, A ;

Angarano, G ;

Chiodo, F ;

Fiori, G ;

Carosi, G .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) :1346-1349

[9]

*US PHS INF DIS SO, 2004, GUID PREV OPP INF PE

[10]

2001, B EPIDEMIOLOG HEBDOM, V24, P111

← 1 →